Methylation status of TUSC3 is a prognostic factor in ovarian cancer

被引:49
|
作者
Pils, Dietmar [1 ]
Horak, Peter [2 ,3 ]
Vanhara, Petr [2 ,3 ]
Anees, Mariam [2 ,3 ]
Petz, Michaela [2 ,3 ]
Alfanz, Angela [2 ,3 ]
Gugerell, Alfred [2 ,3 ]
Wittinger, Michael [2 ,3 ]
Gleiss, Andreas [4 ]
Auner, Veronika [1 ]
Tong, Dan [1 ]
Zeillinger, Robert [4 ]
Braicu, Elena-Ioana [5 ]
Sehouli, Jalid [5 ]
Krainer, Michael [2 ,3 ]
机构
[1] Med Univ Vienna, Div Gynecol, Dept Obstet & Gynecol, A-1090 Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med 1, A-1090 Vienna, Austria
[3] Med Univ Vienna, Ctr Comprehens Canc, A-1090 Vienna, Austria
[4] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, A-1090 Vienna, Austria
[5] Charite Med Univ Berlin, Dept Gynecol & Obstet, Berlin, Germany
基金
奥地利科学基金会;
关键词
TUSC3; methylation; ovarian cancer; glycosylation; progression-free survival; overall survival; biomarker; DNA METHYLATION; HOMOZYGOUS DELETIONS; GLYCOSYLATION; RECOMMENDATIONS; CARCINOMA; SUBUNITS; ORIGIN; GENES; CELLS; OST3P;
D O I
10.1002/cncr.27850
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Current prognostic information in ovarian cancer is based on tumor stage, tumor grade, and postoperative tumor size. Reliable molecular prognostic markers are scarce. In this article, the authors describe epigenetic events in a frequently deleted region on chromosome 8p22 that influence the expression of tumor suppressor candidate 3 (TUSC3), a putative tumor suppressor gene in ovarian cancer. METHODS. Messenger RNA expression and promoter hypermethylation of TUSC3 were studied in ovarian cancer cell lines and in tumor samples from 2 large, independent ovarian cancer cohorts using polymerase chain reaction-based methods. RESULTS. The results indicated that TUSC3 expression is decreased significantly because of promoter methylation in malignant ovarian tumors compared with benign controls. Almost 33% of ovarian cancer samples had detectable TUSC3 promoter methylation. Furthermore, methylation status of the TUSC3 promoter had a significant and independent influence on progression-free and overall survival. CONCLUSIONS. TUSC3 hypermethylation predicted progression-free and overall survival in ovarian cancer. The current observations suggested a role for N-glycosylating events in ovarian cancer pathogenesis in general and identified the epigenetic silencing of TUSC3 as a prognostic factor in this disease. Cancer 2013. (c) 2012 American Cancer Society.
引用
收藏
页码:946 / 954
页数:9
相关论文
共 50 条
  • [41] Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis
    Ruxia Deng
    Xiansheng Lu
    Chang Hong
    Rui Cai
    Ping Wang
    Le Xiong
    Xiaoyu Wang
    Qiaoyu Chen
    Jie Lin
    [J]. Journal of Translational Medicine, 20
  • [42] Mammalian MagT1 and TUSC3 are required for cellular magnesium uptake and vertebrate embryonic development
    Zhou, Hao
    Clapham, David E.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (37) : 15750 - 15755
  • [43] Downregulation of TUSC3 promotes EMT and hepatocellular carcinoma progression through LIPC/AKT axis
    Deng, Ruxia
    Lu, Xiansheng
    Hong, Chang
    Cai, Rui
    Wang, Ping
    Xiong, Le
    Wang, Xiaoyu
    Chen, Qiaoyu
    Lin, Jie
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [44] PLOIDY AS A PROGNOSTIC FACTOR IN OVARIAN-CANCER
    FRIEDLANDER, ML
    TAYLOR, IW
    RUSSELL, P
    MUSGROVE, EA
    HEDLEY, DH
    TATTERSALL, MHN
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1983, 2 (01) : 55 - 63
  • [45] Thrombocytosis as a poor prognostic factor in ovarian cancer
    Jorgensen, T.
    Teiblum, S. T.
    Paludan, M.
    Poulsen, L. O.
    Jorgensen, A. Y. S.
    Bruun, K. H.
    Herrstedt, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S718 - S718
  • [46] Methylation profile as a prognostic factor in advanced gallbladder cancer
    Roa, Juan Carlos
    Anabalon, Leonardo
    Castillo, Johnatan
    Melo, Angelica
    Garcia, Patricia
    Carlos, Manterola
    Sanhueza, Antonio
    Roa, Ivan
    Araya, Juan Carlos
    Villaseca, Miguel
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A321 - A322
  • [47] Methylation profile as a prognostic factor in advanced gallbladder cancer
    Roa, J.
    Garcia, P.
    Sanhueza, A.
    Manterola, C.
    Araya, J.
    Vilaseca, M.
    Guzman, P.
    Anabalon, L.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII62 - VII63
  • [48] BRCA1 Promoter Methylation Status in Ovarian Cancer
    Nikbakht, Mahdi
    Shabanizadeh, Ahmad
    Salehi, Mansour
    Talebi, Ardeshir
    Arababadi, Mohammad Kazemi
    Dahim, Hajar
    Kennedy, Derek
    [J]. LABMEDICINE, 2012, 43 (04): : 122 - 124
  • [49] CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer
    Li, Tianren
    Xue, Hui
    Guo, Yi
    Guo, Kejun
    [J]. ONCOLOGY REPORTS, 2014, 31 (04) : 1825 - 1831
  • [50] miRNA-mediated TUSC3 deficiency enhances UPR and ERAD to promote metastatic potential of NSCLC
    Jeon, Young-Jun
    Kim, Taewan
    Park, Dongju
    Nuovo, Gerard J.
    Rhee, Siyeon
    Joshi, Pooja
    Lee, Bum-Kyu
    Jeong, Johan
    Suh, Sung-suk
    Grotzke, Jeff E.
    Kim, Sung-Hak
    Song, Jieun
    Sim, Hosung
    Kim, Yonghwan
    Peng, Yong
    Jeong, Youngtae
    Garofalo, Michela
    Zanesi, Nicola
    Kim, Jonghwan
    Liang, Guang
    Nakano, Ichiro
    Cresswell, Peter
    Nana-Sinkam, Patrick
    Cui, Ri
    Croce, Carlo M.
    [J]. NATURE COMMUNICATIONS, 2018, 9